Moderna (MRNA) Competitors $31.58 -1.29 (-3.92%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$31.55 -0.03 (-0.09%) As of 07:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRNA vs. CRSP, CVAC, HOOD, NVAX, OCGN, TSLA, JNJ, MRK, PFE, and ARGXShould you be buying Moderna stock or one of its competitors? The main competitors of Moderna include CRISPR Therapeutics (CRSP), CureVac (CVAC), Robinhood Markets (HOOD), Novavax (NVAX), Ocugen (OCGN), Tesla (TSLA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), and argenex (ARGX). Moderna vs. Its Competitors CRISPR Therapeutics CureVac Robinhood Markets Novavax Ocugen Tesla Johnson & Johnson Merck & Co., Inc. Pfizer argenex CRISPR Therapeutics (NASDAQ:CRSP) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation. Which has better earnings and valuation, CRSP or MRNA? CRISPR Therapeutics has higher earnings, but lower revenue than Moderna. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$35M130.11-$366.25M-$4.52-11.67Moderna$3.24B3.77-$3.56B-$8.73-3.62 Is CRSP or MRNA more profitable? Moderna has a net margin of -105.67% compared to CRISPR Therapeutics' net margin of -1,023.64%. CRISPR Therapeutics' return on equity of -20.08% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,023.64% -20.08% -17.13% Moderna -105.67%-28.69%-21.94% Do analysts recommend CRSP or MRNA? CRISPR Therapeutics currently has a consensus target price of $71.75, suggesting a potential upside of 36.07%. Moderna has a consensus target price of $46.61, suggesting a potential upside of 47.60%. Given Moderna's higher possible upside, analysts clearly believe Moderna is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.53Moderna 4 Sell rating(s) 17 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Do insiders and institutionals have more ownership in CRSP or MRNA? 69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor CRSP or MRNA? In the previous week, Moderna had 10 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 26 mentions for Moderna and 16 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.85 beat Moderna's score of 0.74 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 13 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CRSP or MRNA? CRISPR Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. SummaryModerna beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks. Get Moderna News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRNA vs. The Competition Export to ExcelMetricModernaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.71B$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-3.6220.2228.5419.58Price / Sales3.77299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book1.117.568.145.54Net Income-$3.56B-$55.11M$3.24B$257.73M7 Day Performance-3.69%3.81%0.18%-0.08%1 Month Performance21.46%11.60%5.96%8.09%1 Year Performance-74.76%-2.11%26.24%13.02% Moderna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRNAModerna4.2776 of 5 stars$31.58-3.9%$46.61+47.6%-74.0%$12.71B$3.24B-3.625,800Analyst ForecastAnalyst RevisionGap UpCRSPCRISPR Therapeutics3.2296 of 5 stars$50.78-2.7%$71.75+41.3%-8.2%$4.38B$37.31M-11.23460Analyst RevisionCVACCureVac4.7246 of 5 stars$5.44-0.3%$6.83+25.7%+50.3%$1.22B$579.18M5.91880Positive NewsHOODRobinhood Markets3.286 of 5 stars$92.77-1.7%$69.76-24.8%+315.8%$82.24B$2.95B52.772,300Trending NewsAnalyst ForecastInsider TradeNVAXNovavax4.3324 of 5 stars$6.63-2.6%$17.00+156.6%-54.5%$1.07B$682.16M2.501,990Positive NewsOCGNOcugen1.3818 of 5 stars$0.92-4.0%$6.00+552.9%-44.0%$268.08M$4.05M-4.8380TSLATesla4.6897 of 5 stars$291.99-7.4%$301.60+3.3%+23.0%$1.02T$95.72B160.42125,665Trending NewsUpcoming EarningsJNJJohnson & Johnson4.9391 of 5 stars$155.34-0.4%$170.88+10.0%+4.1%$373.69B$88.82B17.28138,100Trending NewsMRKMerck & Co., Inc.4.9962 of 5 stars$81.22+0.4%$109.19+34.4%-36.4%$203.86B$64.17B11.8275,000Positive NewsPFEPfizer4.9647 of 5 stars$25.25-0.5%$28.55+13.1%-15.4%$143.52B$63.63B18.2981,000Trending NewsARGXargenex4.4842 of 5 stars$542.41-0.2%$728.06+34.2%+20.4%$33.10B$2.25B33.441,599Positive NewsAnalyst Revision Related Companies and Tools Related Companies CRISPR Therapeutics Alternatives CureVac Alternatives Robinhood Markets Alternatives Novavax Alternatives Ocugen Alternatives Tesla Alternatives Johnson & Johnson Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives argenex Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRNA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moderna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRNA Stock Alerts